• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call

    7/16/24 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email

    Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7th, at 9:00 a.m. ET.

    Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

    About Charles River

    Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240716352337/en/

    Get the next $CRL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    5/23/2025$182.00Neutral → Buy
    Redburn Atlantic
    5/14/2025$179.00Hold → Buy
    TD Cowen
    5/8/2025$170.00In-line → Outperform
    Evercore ISI
    3/21/2025$190.00 → $170.00Buy → Neutral
    Goldman
    3/4/2025$155.00 → $175.00Sell → Neutral
    Citigroup
    3/3/2025$188.00Sell → Neutral
    Redburn Atlantic
    1/22/2025Outperform → Mkt Perform
    William Blair
    1/17/2025$250.00 → $185.00Buy → Neutral
    UBS
    More analyst ratings

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Mintz Mark claimed ownership of 6,350 shares (SEC Form 3)

      3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      6/10/25 4:22:44 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, Corp Strategy & Develop Laplume Joseph W gifted 385 shares, decreasing direct ownership by 1% to 25,316 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      6/9/25 4:21:38 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Ceesay Abraham was granted 946 shares (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      6/4/25 4:45:04 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:41:25 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:38:37 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      11/21/23 5:07:01 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    SEC Filings

    See more
    • Charles River Laboratories International Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/23/25 4:12:28 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SD filed by Charles River Laboratories International Inc.

      SD - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/16/25 4:09:14 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.

      SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      5/12/25 10:44:44 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Charles River upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00

      5/23/25 8:13:14 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River upgraded by TD Cowen with a new price target

      TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00

      5/14/25 8:48:54 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00

      5/8/25 8:24:10 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

      A solution for laboratories seeking to reduce single-use plastic waste Charles River Laboratories International, Inc. (NYSE:CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River's Endosafe® bacterial endotoxin testing (BET) cartridge technology an avenue to responsibly recycle single-use plastic cartridges used specifically for routine water testing. The cartridge recycling program reaffirms Charles River's ongoing commitment to minimize the Company's environmental footprint and offer a service to assist clients in

      6/16/25 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories to Present at William Blair and Jefferies Conferences

      Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available fo

      6/2/25 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

      Charles River Laboratories International, Inc. (NYSE:CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington's disease (HD), a genetic neurological disorder that causes the progressive dysfunction of nerve cells in the brain. The extension in 2025, marking the 20-year anniversary of the collaboration, will allow more flexible activity across Charles River's global network of scientific expertise and provide greater integration into CHDI's programs. "For two decades, we've been proud to be close partners of CHDI,"

      5/28/25 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care